Ginkgo Bioworks (Altar acquisition)

Ginkgo Bioworks (Altar acquisition)

Ginkgo Bioworks (Altar acquisition)

Description

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals (french laboratory to provide further capabilities to customers in adaptive laboratory evolution)

Ginkgo Bioworks (Altar acquisition)

Address

91000 Evry-Courcouronnes, Ile de France, France

Contact

Description

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals (french laboratory to provide further capabilities to customers in adaptive laboratory evolution)

Matchmaking

Connect with Ginkgo Bioworks (Altar acquisition)

This entity is yours?

Update information

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Ginkgo Bioworks (Altar acquisition) last news

24/01/2024

Automating Evolution: Why ALE?

Automated ALE harnesses the power of evolution (part 1 of 3) Adaptive Laboratory Evolution (ALE) was developed in the mid-20th century, but it's only recently that scientists have been able to leverage this process for industrial partners. Ginkgo's head of ALE, Simon Trancart, discusses how Ginkgo uses ALE as a fast, unbiased strain development tool […] The post Automating Evolution: Why ALE? appeared first on Ginkgo Bioworks .

10/01/2024

Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference

Today we're thrilled to provide updates on our business at the J.P. Morgan Healthcare Conference in San Francisco, live and on webcast at 9:45am PT/12:45pm ET. In short, we: I'm very pleased with the robust revenue and program growth we have seen in 2023, particularly in the biopharma sector – growing the portion of our […] The post Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference appeared first on Ginkgo Bioworks .

08/01/2024

Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board

Today we're thrilled to announce the formation of our new Biopharma Advisory Board! This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo's core platform service offerings across target discovery, drug discovery, optimization, and manufacturing. The group, which will conduct regular meetings at Ginkgo and with its […] The post Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board appeared first on Ginkgo Bioworks .